From the Research
DHEA (Dehydroepiandrosterone) is generally not recommended for patients with Chronic Kidney Disease (CKD) due to safety concerns. There is limited research on DHEA use specifically in CKD patients, and the altered metabolism and clearance of hormones in kidney disease creates potential risks. DHEA is metabolized primarily in the liver, but its metabolites are excreted through the kidneys, which could lead to accumulation in CKD patients. This supplement may also interact with medications commonly prescribed for CKD, including antihypertensives and immunosuppressants. Additionally, DHEA can affect hormone levels, potentially worsening conditions like hypertension that are already problematic in CKD. Patients with CKD often have complex hormonal imbalances, and introducing DHEA could further complicate these issues. If a CKD patient is considering DHEA for symptoms like fatigue or decreased libido, they should instead discuss FDA-approved treatments with their nephrologist and explore underlying causes of these symptoms, which might be related to their kidney disease itself or to conditions like anemia or depression that commonly accompany CKD.
Some studies have investigated the use of DHEA in patients with adrenal insufficiency, suggesting potential benefits in improving mood, fatigue, and well-being 1. However, these findings may not be directly applicable to patients with CKD, and the potential risks associated with DHEA use in this population must be carefully considered. The management of CKD involves a range of strategies to reduce cardiovascular risk, slow disease progression, and manage symptoms, and the use of DHEA is not a recommended part of this approach 2.
In light of the limited evidence and potential risks, CKD patients should avoid using DHEA supplements and instead focus on evidence-based treatments for their condition. This may include lifestyle modifications, such as smoking cessation, weight loss, and regular physical activity, as well as medications to control blood pressure, lipid levels, and glycemic control 2. Patients with CKD should work closely with their healthcare provider to develop a personalized treatment plan that addresses their unique needs and minimizes potential risks.